The U.S. Food and Drug Administration approved Daiichi Sankyo Co. Ltd.’s Turalio for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

Novartis released positive data from the company’s FUTURE 5 clinical trial of Cosentyx (secukinumab) in psoriatic arthritis.

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

For many people with a tear in the rubbery cartilage that cushions the knee, physical therapy may work just as well as surgery in terms of quieting pain and returning the joint’s function, a new study suggests.

Eli Lilly announced the results of the company’s COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat ankylosing spondylitis. The study met both primary and major secondary endpoints.

Oral glucosamine – a natural supplement often marketed for joint pain – has no more effect than a dummy pill, according to a new review of available research.

Eli Lilly and Company and Incyte Corporation announced a new pooled analysis of data from eight Olumiant (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis had similar rates of serious infection incidents.

Doctors might one day be able to harvest cells from patients’ noses to produce cartilage that can be transplanted into damaged knee joints.

Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study. The oral drug, CR845, was being evaluated in patients with osteoarthritis in the knee or hip, the company said on Wednesday. Osteoarthritis, also known as degenerative arthritis, is a type of disease that results […]

The U.S. Food and Drug Administration on Tuesday approved Baxalta Inc’s Vonvendi, making it the first engineered protein-based treatment for the world’s most common inherited bleeding disorder. Vonvendi treats Willebrand disease, which is caused by the deficiency or defect in von Willebrand factor, a protein that is critical for blood clotting. The disease affects about […]